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Abstract Non-specific immunotherapy has been for a
long time a standard treatment option for patients with
metastatic renal cell carcinoma but was redeemed by spe-
cific targeted molecular therapies, namely the VEGF and
mTOR inhibitors. After moving treatment for mRCC to
specific molecular agents with a well-defined mode of
action, immunotherapy still needs this further development
to increase its accuracy. Nowadays, an evolution from a
rather non-specific cytokine treatment to sophisticated
targeted approaches in specific immunotherapy led to a
re-launch of immunotherapy in clinical studies. Recent
steps in the development of immunotherapy strategies are
discussed in this review with a special focus on peptide
vaccination which aims at a tumor targeting by specific T
lymphocytes. In addition, different combinatory strategies
with immunomodulating agents like cyclophosphamide or
sunitinib are outlined, and the effects of immune check-
point modulators as anti-CTLA-4 or PD-1 antibodies are
discussed.
Keywords Renal cell carcinoma  Tyrosine kinase
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Introduction
The observation of rare spontaneous tumor regressions in
RCC has led to the early assumption that RCC is an
immunogenic tumor [1]. Additionally, RCC tumors
express higher levels of HLA class I and class II mol-
ecules compared to non-tumoral tissue [2, 3]. RCC tissue
is frequently infiltrated by immune cells especially
functional T lymphocytes [4, 5]. Therefore, strategies
which harness the adaptive immune system were early
considered as promising therapeutic options. Non-specific
immunotherapy with the cytokines interleukin-2 (IL-2)
and/or interferon-alpha (IFN-a) has been largely used in
the past 25 years with the result of a notable clinical
benefit (disease stabilization or remission) reported in up
to one-third of treated patients. Long-term complete
responders (CRs) are rare, but regularly observed [8].
However, median survival is only marginally enhanced,
so non-specific immunotherapy is rarely used nowadays
[6, 7]. In high-dose IL-2-treated patients, retrospective
analyses proposed both high carbonic anhydrase IX and
a pathologic risk classification based on extent of the
alveolar morphology to forecast CR [8, 9]. These fea-
tures were prospectively evaluated in the SELECT trial,
but the predictive value of these putative biomarkers was
not confirmed. Additionally, increased frequencies of
regulatory T cells (Treg) and decreased frequencies of
circulating myeloid and plasmacytoid dendritic cells have
been reported in cytokine-treated mRCC patients and
may partly explain the limitations of such therapy
[10, 11].
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Targeted therapy
While enthusiasm for non-specific immunotherapies damp-
ened, the discovery of the Von-Hippel–Lindau (VHL) gene
and of its related molecular pathways and mechanisms built
the basis for the era of ‘‘targeted’’ therapy [12]. Since 2005,
different tyrosine kinase (TK) inhibitors targeting the VEGF
receptor and mammalian target of rapamycin (mTOR)
inhibitors have been successively introduced in the clinical
routine for the treatment of mRCC patients [13]. Both
median progression-free (PFS) and overall survival (OS) are
substantially prolonged with these new substances, exceed-
ing significantly the results obtained during the cytokine era.
However, a profound prolongation of survival leading to
long-term survivors has not been described so far. In addi-
tion, the prolongation of OS is compromised by drug-
induced side effects which lead to dose interruption in up to
38 % of the patients [12, 14]. Due to this limited improve-
ment of TK or mTOR inhibitors in the long-term, new
therapy options are required to further improve patients’
cancer-specific survival (CSS).
Interestingly, it was observed that targeted agents do not
only inhibit angiogenesis and tumor cell proliferation, but
also show immunomodulatory effects directing the immune
system to a stronger anti-tumor response [15]. For instance,
sunitinib-treated mRCC patients show decreased frequen-
cies of Tregs and myeloid-derived suppressor cells (MDSCs)
in the peripheral blood [16, 17]. At the same time, sunitinib
may shift T-helper cells toward a Th1-type response [16]. In
contrast, sorafenib has immunosuppressive effects with a
reduced induction of antigen-specific T cells in vitro and in
immunized mice [15, 18]. Additionally, mTOR antagonists
inhibit the calcineurin-dependent activation of the IL-2 gene
transcription in response to T-cell receptor activation [19].
Therefore, combining the compatible targeted agents with
immune therapy appears like a promising therapeutic option,
especially if the non-specific immune stimulation can be
redirected toward a more specific, efficient and durable
adaptive immunity against tumor cells.
Specific immunotherapy
Cytokine therapy with IL-2 and IFN-a non-specifically
activates the immune system. This immune therapy does
not present a very well-defined mode of action and does not
induce a specific T-cell response directed toward known
tumor-associated antigens (TAAs). Because of that, spe-
cific biomarkers or assays for immune monitoring of
tumor-directed T cells cannot be available to monitor
response to therapy. More importantly, due to its non-
specific nature, the efficacy of such immunotherapy is
limited, while the adverse events are substantial. It would
be therefore highly desirable to activate effector T lym-
phocytes, especially cytotoxic CD8? T cells, against
tumoral, but not healthy tissues while inducing a long-
lasting memory response against cancer cells. This can
only be efficiently achieved by directing these T cells
toward target structures specifically expressed or overex-
pressed in tumor cells.
Tumor-associated antigens
It is well known that TAAs expressed by tumor cells can be
very specifically recognized by the T-cell receptor (TCR)
of cytotoxic CD8? T lymphocytes. TCRs can bind spe-
cifically to short peptides of typically 8–10 amino acids in
length derived from intracellular proteins and presented by
human leukocyte antigen (HLA) molecules on the cell
surface. Cell antigen processing leads to the display of such
HLA-restricted peptides derived from TAAs, also known
as tumor-associated peptides (TUMAPs). For generating
TUMAPs, two main steps are necessary: First, the cleavage
of the protein within the tumor cell by specific proteases
must generate the peptide itself or a slightly longer pre-
cursor, and second, this peptide must contain a so-called
HLA peptide motif for loading into the groove of the rel-
evant HLA class I allele (Fig. 1a) [20]. Therefore, such
HLA–peptide complexes represent suitable targets against
which the host’s immune system can be activated in order
to eliminate tumor cells.
In cancer vaccination, the choice of targeted TAAs is
therefore crucial. The tumor specificity of cancer germ-
line antigens (CTAs) is due to the fact that they are
expressed in male germ cells and trophoblastic tissues,
but not in other normal adult tissues except some tumor
types. The cancer germ-line antigen MAGE-1 was the
first TAA identified as a target of human CD8? T cells
and proved the concept of specific tumor recognition in
patients [21]. Overexpressed antigens are those present in
benign tissue, but at a significantly higher level on tumor
cells. In RCC, carbonic anhydrase IX (CA IX) and
Apolipoprotein L1 are such TAAs and appear particularly
interesting since the presence of the T-cell epitopes
derived from such TAAs has been confirmed in tumor
tissue by analytical methods [22]. Another class of anti-
gens results from mutated proteins. These are especially
interesting for specific immunotherapy, since they are
unique and solely expressed by the tumor cells. Mutation
in the tumor protein sequence enables either a peptide to
bind to HLA while the ‘‘wild-type’’ sequence does not or
the new amino acid sequence induces a highly ‘‘mutation-
specific’’ T-cell response. The great advantage of such
mutated antigens lies in their true tumor specificity,
potentially no triggering of peripheral tolerance and their
frequent occurrence in driver genes decreasing the risk of
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immune escape due to the loss of expression [23].
Moreover, it can be assumed that specific T cells have not
been subjected to T-cell deletion during thymus devel-
opment and do not have been subjected to central toler-
ance. However, the uniqueness of TAA mutations may
also be seen as a disadvantage, since they must be
identified in each individual mRCC patient. However,
recent technological progresses are paving the way to a
fully individualized immunotherapy approach in the
foreseeable future.
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Fig. 1 a Presentation of tumor-
associated antigens. b Specific
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checkpoints in RCC
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Autologous tumor immunotherapy
Based on the knowledge that the immune system, for
example, the cytotoxic CD8? T cells, can be specifically
directed against TAAs, different vaccines consisting of
professional antigen-presenting cells [i.e., dendritic cells
(DCs)] loaded with either allogeneic or autologous tumor-
derived lysates or RNA with or without alongside admin-
istration of IL-2 were tested [24, 25].
The autologous tumor cell lysate vaccine Reniale
(Liponova, Hanover, Germany) was evaluated in the
adjuvant setting in high-risk RCC after nephrectomy. Five-
year PFS was significantly improved as compared to
observation (77.4 vs. 67.8 %), but the vaccine was not
approved by the EMA for various reasons, including issues
in trial methodology [26, 27]. Another adjuvant phase III
trial assessed the efficacy of Vitespen, an autologous
tumor-derived heat shock protein Gp96 preparation
(Oncophage. Antigenics Inc., Lexington, MA), and failed
to reach the primary endpoint of PFS prolongation, despite
some indication of activity in retrospectively defined sub-
groups [28].
Adoptive T-cell transfer represents another, consider-
ably successful strategy in tumor immunotherapy. It is
known that often tumor-infiltrating lymphocytes (TIL) are
present within the RCC tumor tissue [4]. The presence of
TILs suggests that the patient’s immune system has been
activated to fight the tumor. Adoptive T-cell transfer of
in vitro selected and/or expanded anti-tumor T cells is an
approach to provoke a graft versus host reaction. The
transplanted T cells attack the tumor which will be rec-
ognized, for example, as foreign tissue. Results of this
approach are limited in RCC with no improvement of OS
in phase I/II studies [29]. The genetic reprogramming of T
cells has demonstrated promising preclinical data [30].
Immune biomarkers
Tumor-based approaches such as those mentioned above
are characterized by the use of a complex mixture of
undefined proteins, potentially including many undefined
TAAs presented by several HLA alleles. Such vaccines
have the intrinsic limitation that the TAAs that are pro-
cessed and then displayed on the surface of the APCs are
different in the individual patients and therefore it is
unknown against which TAA-specific T cells might be
activated. Consequently, due to the unknown TAAs,
monitoring of vaccine immunogenicity is inherently diffi-
cult and mostly incomplete. This is disappointing, since
measurement of T cells or even antibodies is of critical
importance to assess the effects of the vaccine on the
immune system, to compare the efficacy of various clinical
approaches and, hopefully in the near future, to predict
therapy efficacy. To achieve these ambitious aims, in vitro
immunomonitoring should be robust, reproducible and
sensitive; however, up to now, no particular assay has been
designed as being the gold standard to be applied. The
Immunoguiding Program of the Association for Immuno-
therapy of Cancer (CIP/CIMT) is an international network
working on the harmonization of the methods applied for
in vitro monitoring of T cells among the community [31].
This and further initiatives should help to compare vaccine
strategies and to accelerate progresses in the field [32, 33].
Meanwhile, several studies indeed demonstrate a correla-
tion between vaccine immunogenicity measured in the
blood and clinical benefit [34, 35].
Single antigen-based tumor vaccines
Some more recent approaches have used defined single
TAA. In the TROVAX renal immunotherapy survival trial
(TRIST), a modified vaccinia Ankara vector engineered to
deliver the tumor antigen 5T4 (MVA-5T4; TroVaxTM,
Oxford BioMedica, Oxford, UK) was evaluated in a phase
III study in combination with sunitinib, plus interleukin-2
or interferon-a. However, the primary endpoint of OS was
not reached (median 20.1 vs. 19.2 months; TROVAX vs.
placebo) [36]. One potential reason maybe that immune
evasion by target down modulation which is more likely
with a single antigen is being targeted [37].
Multi-antigen peptide-based vaccination
Vaccination of RCC patients with synthetic peptides rep-
resenting TAA-derived T-cell epitopes, that is, TUMAPs,
presents several advantages: First, the manufacturing of
synthetic peptides is relatively easy and cost-effective and
they are very stable allowing long-term storage. Second, as
shown by multiple vaccination trials in various cancer
types so far, they are safe [34, 38]. Moreover, in vitro
immunomonitoring of TUMAP-specific T cells is possible
since the target structures recognized by the T cells are
well defined. And fourth, the mixture of several peptides of
different TAAs virtually allows covering a broad range of
antigens with the result of a decreased risk of an immu-
nological tumor escape.
Peptides can be either loaded ex vivo onto patient’s
autologous DCs which will then be given back to the patient,
or injected directly by intradermic or subcutaneous admin-
istration, where the peptides will be taken up by skin-resident
DCs [25]. In theses approaches, optimal DCs activation and
migration to the regional lymph node is crucial and can be
supported by the administration of immunological adjuvants
and/or immunomodulators (Fig. 1b).
A recent vaccine development following this principle
for mRCC is IMA901, which consists of nine TUMAPs
34 World J Urol (2014) 32:31–38
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restricted by HLA-A*02 and one pan-HLA-DR-binding
class II peptide. In two multicenter phase I and II trials,
IMA901 was tested for safety, immunogenicity and T-cell
response in association with a clinical benefit [34]. In the
first phase I trial, 16 patients progressed, 11 had stable
disease and 1 showed a partial response out of 28 patients
enrolled after 3-month follow-up. None of the patients
evaluable for the safety analysis experienced a drug-related
severe adverse event. Among the 27 immune-evaluable
patients those who responded to several TAAs, at least two
were more likely to experience a clinical benefit. Addi-
tionally, low blood levels of regulatory T cells (CD4?
Foxp3? Tregs) before the start of therapy were correlated to
a multiple T-cell response after vaccination [34].
A total of 68 patients of the phase II study had pro-
gressive disease after at least one previous cytokine and/or
TKI pretreatment. Patients were randomized 1:1 to receive
IMA901± a low-dose cyclophosphamide (Cy) pretreat-
ment with the aim to reduce levels of Tregs and boost the
immunological benefit of the vaccine. The rate of immune
responders (64 %) was similar to that of the first trial, with
26 % of patients responding to more than one TAA.
Although Cy did not improve the rate of immune
responders, Cy-pretreated patients showed a prolonged
median OS of 23.5 months (vs. 14.8 months without Cy).
In a subgroup analysis of immune- and non-responders
with or without the addition of Cy, only patients who
exhibited an immune response to the vaccine showed a
benefit from Cy pretreatment. This indicates that Cy has no
single-agent activity but rather acts as an immunomodu-
lator of the vaccine [34]. In this study, OS positively cor-
related with the number of induced T-cell responses.
Nevertheless, the mechanisms to induce a multi-T-cell
response could not be fully determined as the Cy approach
did not increase peripheral immune responses.
This work is the first to demonstrate a clear association
between an induced anti-TUMAP T-cell response and a
clinical benefit measured as prolonged OS in mRCC.
Moreover, it illustrates that a careful immunomonitoring
can constitute a rational basis to modify therapies for
improving patient’s benefit.
Hurdles in peptide vaccination
Currently, there are several challenges in peptide vacci-
nation: Which TAA should be targeted and in which format
(long vs. short peptides, induction of CD8? or CD4?
T-cell epitopes)? How can an efficient T-cell response in
terms of dosage, route of administration and choice of
adjuvants/immunomodulators be induced? And how can
this response be sustained over time, for example, by the
vaccination schedule?
HLA restriction
A possible disadvantage of peptides is their HLA restric-
tion limiting the eligibility of patients in clinical trials.
However, with the advancement of formulation technolo-
gies, the next generation of peptide vaccines will be
composed of peptides restricted to a number of the most
common HLA alleles allowing coverage of greater than
90 % of the patient population. Currently, more and more
non-HLA-A*02 TUMAPs are identified and tested in RCC
for their immunologic response [39, 40]. Moreover, new
technologies of next-generation sequencing coupled with
improvements in mass spectrometry will allow the identi-
fication of the entire HLA ligandome, including mutation-
derived sequences in individual patients in the near future.
This will allow the use of TUMAPs derived from mutated
tumor proteins which seems to be very robust in their
presentation on the tumor cell surface [23].
Choice of the immunomodulators/adjuvants
The adjuvant’s role is to enhance the immunogenicity of
the administered vaccine and can be differentiated from
systemic immunomodulators as the adjuvants are locally
and temporally restricted co-administered with the TUM-
APs [23]. For instance, skin-resident DCs shall be boosted
in their antigen loading and presentation, activation, and
migration to the draining lymph node. Locally co-admin-
istered Montanide and GM-CSF are commonly used to
trigger these processes, but only few studies have directly
compared these substances. In addition, the reported effects
of the widely used GM-CSF are contradictory as it might
enhance T-cell response, but was also shown to lower it if
used at high systemic doses [23, 41, 42]. Currently, trig-
gering through Toll-like receptors (TLRs) is a favored
option, and we also observed that TLR7 stimulation by
imiquimod seems to increase clinical response rate in
prostate carcinoma peptide vaccination [38].
Immunological checkpoints and combination strategies
with immunotherapy
The tumor microenvironment has developed a plethora of
strategies to impair T-cell activation and silence activated
T cells, which also prevent an effective immune response
after vaccination [43, 44]. Tumor-driven immune sup-
pression includes the downregulation of HLA molecules
and/or TAA, which leads to a decreased immunogenicity or
the induction of suppressive cytokines like IL-10 or TGF-b
[43]. In addition, these factors can recruit Tregs, MDSCs or
tumor-associated M2 macrophages, which in turn again act
in an immunosuppressive manner [45, 46]. Therefore,
World J Urol (2014) 32:31–38 35
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agents called immunomodulators or checkpoint inhibitors,
which counteract tumor-induced immunosuppression, may
raise the efficacy of immunotherapy. Several checkpoints
controlling T-cell activation are well known, and clinical
application of inhibitors has already shown remarkable
success in cancer treatment (Fig. 1c).
One costimulatory cascade essential for efficient
T-cell activation is elicited by the binding of CD80 and
CD86 on the DC to CD28 on the T cell which is
inhibited if CD80/86 binds to the inhibitory molecule
cytotoxic T-lymphocyte antigen 4 (CTLA-4) expressed
on activated T cells (Fig. 1c). The antibodies treme-
limumab and ipilimumab are directed against CTLA-4
and thereby re-activate effector T cells. Currently, ipi-
limumab is only approved as monotherapy for the
treatment for metastatic melanoma [47]. In a phase II
trial of mRCC patients, it was shown to induce a partial
response in 5 of 40 patients [48].
Another immune escape mechanism uses the PD-1
receptor. Tumor cells can express PD ligand-1 to silence
T-cell activation. A humanized anti-PD-1 antibody has
already shown promising effects in a phase I study
including mRCC patients and is currently evaluated in
further studies in mRCC [49, 50].
LAG-3 (CD223) is expressed on activated T cells and is
involved in the downregulation of antigen-induced TCR
activation, negatively regulating T-cell function and
homeostasis. As a soluble recombinant humanized form
(IMP321, sLAG-3-Ig), it activates APCs through MHC
class II signaling [51]. In a phase I mRCC trial, IMP321
induced a sustained CD8? T-cell activation and increased
the percentage of long-lived effector memory CD8? T
cells at doses above 6 mg which translated to a stable
disease in 7 out of 8 patients [52].
To achieve the maximal benefit for mRCC patients, it is
likely that immunotherapy will need to be combined with
targeted agents, currently approved for first-line therapy, or
with checkpoint blockers or immunomodulators. Bev-
acizumab, an anti-VEGF antibody, in combination with
Interferon-a, is currently the clinically most advanced and
the only approved combination with (non-specific) immu-
notherapy. Two phase III studies demonstrated an
increased OS of the combination as compared to IFN-a
alone (18.3 and 23.3 months) [53, 54].
Using checkpoint inhibitors, the PD-1 targeting antibody
BMS-936558 in combinations of sunitinib or pazopanib
plus anti-PD-1 is evaluated in a phase I study still
recruiting patients [55].
A rather unexpected property of TKIs is their immu-
nomodulatory effect. As an example, sunitinib does not
only inhibit angiogenesis and cell proliferation in mRCC,
but also decreases the number of Tregs and MDSCs while
maintaining DC function [15–17]. One of the advantages in
specific vaccination or immunotherapy is that these treat-
ments are characterized by low to minimal side effects
which makes it easy to combine these together without an
exponential increase in side effects.
Due to the immunomodulatory effect, the combination
with sunitinib is a most challenging approach if compared
to other TKI. AGS-003 is a RNA-loaded dendritic cell-
based vaccine demonstrating a PFS of 11.9 months in a
phase II if combined with sunitinib. Immune monitoring of
AGS-003-treated patients showed an expansion of tumor
antigen-reactive CD28? cytotoxic T lymphocytes and a
decrease in Tregs [56]. For the multipeptide vaccine
IMA901, a large phase III trial has finished the recruitment
of 340 patients who were randomized in a 3:2 fashion to
IMA901 plus sunitinib versus sunitinib alone in first-line
advanced RCC patients. Based on the previous phases I/II,
Cy and GM-CSGF were additionally applied as immuno-
modulators with IMA901. First results are expected in
2014 [57].
Summary and future perspective
The evolution of immunotherapy in RCC has followed a
general refinement from rather non-specific approaches
such as cytokine treatment or tumor cell lysates to the use
of well-defined and selected T-cell targets. Although
promising clinical results have been achieved with peptide-
based vaccination, both clinical benefit and accessibility
for all patients, irrespective of their HLA allele combina-
tion, need to be further improved. Furthermore, therapy is
limited due to the lack of prospective phase III studies.
Peptide vaccination induces a well-defined T-cell response
which can be monitored precisely and was shown to cor-
relate with clinical benefit. The identification of TAAs
expressed with a high tumor tissue specificity, the knowl-
edge of such TAAs suitable for each individual patient, the
adequate in vivo activation of DCs and anti-tumor T cells
are major tasks for the next years.
Currently, the combination of an established first-line
therapy, which ideally not only targets angiogenesis and
cell proliferation, but also presents immunomodulatory
activities, together with a peptide vaccine cocktail
appears as a highly promising strategy in mRCC treat-
ment. In addition, specific checkpoint inhibitors like
PD-1 antibody hold the promise to boost the specific
TAA-directed T-cell response. Here, peptide vaccination
is the new kid on the block in mRCC treatment whose
complex anti-tumor power is currently only visible like
the tip of an iceberg.
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